Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR).

MLA

Blauvelt, A., et al. “Extension of Ustekinumab Maintenance Dosing Interval in Moderate‐to‐severe Psoriasis: Results of a Phase IIIb, Randomized, Double‐blinded, Active‐controlled, Multicentre Study (PSTELLAR).” British Journal of Dermatology, vol. 177, no. 6, Dec. 2017, pp. 1552–61. EBSCOhost, https://doi.org/10.1111/bjd.15722.

APA

Blauvelt, A., Ferris, L. K., Yamauchi, P. S., Qureshi, A., Leonardi, C. L., Farahi, K., Fakharzadeh, S., Hsu, M. ‐C., Li, S., Chevrier, M., Smith, K., Goyal, K., Chen, Y., Muñoz, E. E. J., & Callis Duffin, K. (2017). Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR). British Journal of Dermatology, 177(6), 1552–1561. https://doi.org/10.1111/bjd.15722

Chicago

Blauvelt, A., L. K. Ferris, P. S. Yamauchi, A. Qureshi, C. L. Leonardi, K. Farahi, S. Fakharzadeh, et al. 2017. “Extension of Ustekinumab Maintenance Dosing Interval in Moderate‐to‐severe Psoriasis: Results of a Phase IIIb, Randomized, Double‐blinded, Active‐controlled, Multicentre Study (PSTELLAR).” British Journal of Dermatology 177 (6): 1552–61. doi:10.1111/bjd.15722.